EXTH-101. CAR T-cells targeted to B7-H3 are effective against ependymomas but show limited response in the immune competent setting

Le résumé fourni par la source

Abstract Targeted treatments are desperately needed for ependymomas (EPN). Chimeric antigen receptor (CAR) T-cells have the potential to transform patient outcomes. However, little is known regarding the antitumor efficacy of CAR T-cells against EPNs. We found that B7-H3 is highly and consistently expressed on EPNs, making it a promising CAR T-cell target. The goal of this project is to develop a safe, effective B7-H3-targeted CAR T-cell immunotherapy for EPN. We generated second-generation mouse and human B7-H3-CAR T-cells and examined their anti-EPN functionality in vitro and in vivo. Human B7-H3.CAR T-cells demonstrated in vitro antitumor activity against six EPN cell lines. In repeated-stimulation assays, CAR T-cells remained functional for 7–10 rounds of killing and expanded up to 325,000-fold. Multiplex cytokine analysis revealed sustained Th1 response and a significant increase in Th2 response from the 1st to the 4th stimulation. We found that EPN cells constitutively secrete high levels of C-C motif chemokine ligand 2 (CCL2), which increased significantly (up to 100,000-fold) in co-culture with CAR T-cells. In vivo, 11/17 human B7-H3.CAR-treated mice durably cleared xenograft EPNs, while the remaining animals were treatment refractory. In a fully syngeneic EPN model, despite robust in vitro efficacy, murine B7-H3.CAR T-cells showed in vivo efficacy in only 1/9 mice, which eventually relapsed 76 days after CAR T-cell treatment. IHC analysis of tumors at endpoint revealed robust infiltration of macrophages and microglia within tumors, regardless of treatment. This observation is consistent with CCL2’s role as a major chemoattractant of monocytes and macrophages. Together, our study establishes clinically relevant models to study CAR T-cell therapy resistance in EPN, and preliminary mechanistic insight into CAR T-cell persistence and modulation through CCL2 signaling. Additionally, our work is the first to evaluate CAR T-cell efficacy against EPNs in the syngeneic setting.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.